Restricted accessResearch articleFirst published online 2021-06
Chitosan-Shelled Nanobubbles Irreversibly Encapsulate Morpholino Conjugate Antisense Oligonucleotides and Are Ineffective for Phosphorodiamidate Morpholino-Mediated Gene Silencing of DUX4
Orphan drugs, including antisense oligonucleotides (AONs), siRNAs/miRNAs, Cas9 nuclease, and recombinant genes, have recently been made available for rare diseases. However, the main bottleneck for these new therapies is delivery. Drugs/synthetic genes need to reach the affected tissues with minimal off-target effects and immune reactions. AON molecules are currently delivered as backboned naked compounds or via viral vectors. Nanocarriers are considered promising vehicles, able to improve drug distribution by organ targeting and limiting safety issues.
We tested perfluoropentane-based nanobubbles (NBs) as vehicles for loading phosphorodiamidate morpholino (PMO) AON to suppress DUX4 expression in a facioscapulohumeral muscular dystrophy cell model. In vitro cell-free analysis demonstrated a good loading capacity of PMO into NBs, while experiments in cell cultures showed lack of therapeutic effect since expression of DUX4 and its targets remained unmodified. We conclude that these types of chitosan-shelled NBs do not release PMO-AON and are therefore not ideal for PMO AON-related therapies.
Get full access to this article
View all access options for this article.
References
1.
TambuyzerE, VandendriesscheB, AustinCP, BrooksPJ, LarssonK, Miller NeedlemanK, ValentineJ, DaviesK, GroftSC, et al. (2020). Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov, 19:93–111.
2.
BajanS and HutvagnerG. (2020). RNA-Based Therapeutics: from Antisense Oligonucleotides to miRNAs. Cells 9:pii:. E137.
3.
Aartsma-RusA and KriegAM. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther, 27:1–3.
4.
MartinovichKM, ShawNC, KicicA, SchultzA, FletcherS, WiltonSD and Stick.SM (2018). The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 5:3.
5.
EchevarríaL, AupyP, and GoyenvalleA. (2018). Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet, 27:R163–R172.
6.
ParenteV and Corti.S (2018). Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord, 11:1756285618754501.
7.
MarsollierAC, JoubertR, MariotV and DumonceauxJ. (2018). Targeting the Polyadenylation Signal of Pre-mRNA: a New Gene Silencing Approach for Facioscapulohumeral Dystrophy. Int J Mol Sci 19: pii:. E1347.
8.
DeVosSL and MillerTM. (2013). Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics, 10:486–497.
9.
ShenX and CoreyDR. (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res, 46:1584–1600.
10.
Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res, 44:6518–6548.
11.
GodfreyC, DesviatLR, SmedsrødB, Piétri-RouxelF, DentiMA, DistererP, LorainS, Nogales-GadeaG, SardoneV, et al. (2017). Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med, 9:545–557.
12.
SardoneV, ZhouH, MuntoniF, FerliniA and FalzaranoMS. (2017). Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22:pii:. E563.
13.
FalzaranoMS, FlesiaC, CavalliR, GuiotC, FerliniA. (2018). Nanodiagnostics and Nanodelivery Applications in Genetic Alterations. Curr Pharm Des, 24:1717–1726.
14.
NiuZ, Conejos-SánchezI, GriffinBT, O'DriscollCM, andAlonsoMJ. (2016). Lipid-based nanocarriers for oral peptide delivery. Adv Drug Deliv Rev, 106:337–354.
15.
BennetD, and KSanghyo. (2014). Polymer nanoparticles for smart drug delivery. In: Application of Nanotechnology in Drug Delivery. Ali Demir Sezer, ed. Chapter 8, Intech, Croatia, pp. 458–310.
16.
ChengX, and LeeRJ. (2016). The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev, 99:129–137.
17.
BhattacharyaK, MukherjeeSP, GalludA, BurkertSC, BistarelliS, BellucciS, BottiniM, StarA and FadeelB. (2016). Biological interactions of carbon-based nanomaterials: from coronation to degradation. Nanomedicine, 12:333–351.
18.
RimessiP, SabatelliP, FabrisM, BraghettaP, BassiE, SpitaliP, VattemiG, TomelleriG, MariL, et al. (2009). Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol Ther, 17:820–827.
19.
FerliniA, SabatelliP, FabrisM, BassiE, FalzaranoS, VattemiG, PerroneD, GualandiF, MaraldiNM, et al. (2010). Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. Gene Ther, 17:432–438.
20.
BassiE, FalzaranoS, FabrisM, GualandiF, MerliniL, VattemiG, PerroneD, MarchesiE, SabatelliP, et al. (2012). Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol, 2012:8970–8976.
21.
FalzaranoMS, PassarelliC, BassiE, FabrisM, PerroneD, SabatelliP, MaraldiNM, DonàS, SelvaticiR, et al. (2013). Biodistribution and molecular studies on orally administered nanoparticle-AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice. Biomed Res Int, 2013:527418.
22.
FalzaranoMS, PassarelliC and FerliniA. (2014). Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther, 24:87–100.
23.
CavalliR, BisazzaA, TrottaM, ArgenzianoM, CivraA, DonalisioM, and LemboD. (2012). New chitosan nanobubbles for ultrasound-mediated gene delivery: preparation and in vitro characterization. Int J Nanomed, 7:3309–3318.
24.
BisazzaA, CivraA, DonalisioM, LemboD and CavalliR. (2011). The in vitro characterization of dextran-based nanobubbles as possible DNA transfection agents. Soft Matter, 7:10590–10593.
25.
MaranoF, ArgenzianoM, FrairiaR, AdaminiA, BoscoO, RinellaL, FortunatiN, CavalliR, and CatalanoMG. (2016). Doxorubicin-loaded nanobubbles combined with extracorporeal shock waves: basis for a new drug delivery tool in anaplastic thyroid cancer. Thyroid, 26:705–716.
26.
CavalliR, BisazzaA and LemboD. (2013). Micro- and nanobubbles: a versatile non-viral platform for gene delivery. Int J Pharm, 456:437–445.
27.
ChenJC, KingOD, ZhangY, ClaytonNP, SpencerC, WentworthBM, Jr EmersonCP and WagnerKR. (2016). Morpholino-mediated Knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics. Mol Ther, 24:1405–1411.
28.
DasS and Chadwick.BP (2016). Influence of Repressive Histone and DNA Methylation upon D4Z4 transcription in non-myogenic cells. PLoS One, 11:e0160022.
29.
YaoZ, SniderL, BalogJ, LemmersRJ, Van Der MaarelSM, TawilR and TapscottSJ. (2014). DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Hum Mol Genet, 23:5342–5352.
30.
AnsseauE, VanderplanckC, WautersA, HarperSQ, CoppéeF and BelayewA. (2017). Antisense Oligonucleotides Used to Target the DUX4 mRNA as therapeutic approaches in faciosscapulohumeral muscular dystrophy (FSHD). Genes (Basel) 8:pii:. E93.
31.
MarsollierAC, CiszewskiL, MariotV, PopplewellL, VoitT, DicksonG and DumonceauxJ. (2016). Antisense targeting of 3’ end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach. Hum Mol Genet, 25:1468–1478.
32.
KromYD, DumonceauxJ, MamchaouiK, den HamerB, MariotV, NegroniE, NegroniE, GengLN, MartinN, et al. (2012). Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. Am J Pathol, 181:1387–1401.
33.
MariotV, JoubertR, HourdeC, FeassonL, HannaM, MuntoniF, MaisonobeT, ServaisL, BogniC, et al. (2017). Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun, 8:1859.
34.
LirussiD and MMatrajt. (2011). RNA granules present only in extracellular Toxoplasma Gondii increase parasite viability. Int J Biol Sci, 7:960–967.
35.
RaiR, Alwani S and IBadea. (2019). Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Polymers 11:pii:. E745.
36.
RaemdonckK., MartensTF, BraeckmansK, Demeester and De Smedt SCJ. (2013). Polysaccharide-based nucleic acid nanoformulations. Adv Drug Deliv Rev, 65:1123–1147.
37.
YueZG, WeiW, LvPP, YueH, WangLY, SuZG and MaGH. (2011). Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules, 12:2440–2446.
38.
ForestV and JPourchez. (2017). Preferential binding of positive nanoparticles on cell membranes is due to electrostatic interactions: a too simplistic explanation that does not take into account the nanoparticle protein corona. Mater Sci Eng C, 70:889–896.
39.
FerraraKW, BordenMA and ZhangH. (2009). Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res, 42:881–892.
40.
GeisNA, KatusHA and BekeredjianR. (2012). Microbubbles as a vehicle for gene and drug delivery: current clinical implications and future perspectives. Curr Pharm Des, 18:2166–2183.
41.
WuB, ShangH, LiangX, SunY, JingH, HanX and ChengW. (2019). Preparation of novel targeting nanobubbles conjugated with small interfering RNA for concurrent molecular imaging and gene therapy in vivo. FASEB J, 33:14129–14136.
42.
KhadjaviA, SturaI, PratoM, MineroVM, PanaritiA, RivoltaI, GulinoGR, BessoneF, GiribaldiG, et al. (2018). ‘In Vitro’, ‘In Vivo’ and ‘In Silico’ investigation of the anticancer effectiveness of oxygen-loaded chitosan-shelled nanodroplets as potential drug vector. Pharm Res, 35:75.
43.
BettsC, SalehAF, ArzumanovAA, HammondSM, GodfreyC, CoursindelT, GaitMJ and Wood.MJ (2012). Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids, 1:e38.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
